GSTM1 and chronic kidney disease: The clinical practice patterns for management of anaemia of CKD still remain highly variable with conflicting recommendations from key guideline agencies relating both to optimal Hb targets (Table 1), ESA administration (including the Hb concentration at which patients should begin ESA treatment or have their ESA dose adjusted), iron management and other aspects of ESA treatment (including definitions of ESA resistance, role of inflammation in management of anaemia, etc.).